Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to -$1.31.

  • Lyell Immunopharma's EPS (Weighted Average and Diluted) rose 38.79% to -$2.13 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.32, marking a year-over-year increase of 170.84%. This contributed to the annual value of -$1.31 for FY2024, which is 40.86% down from last year.
  • Latest data reveals that Lyell Immunopharma reported EPS (Weighted Average and Diluted) of -$1.31 as of FY2024, which was down 40.86% from -$0.93 recorded in FY2023.
  • In the past 5 years, Lyell Immunopharma's EPS (Weighted Average and Diluted) registered a high of -$0.74 during FY2022, and its lowest value of -$15.69 during FY2020.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$0.99, with a median of -$0.93 in 2023.
  • As far as peak fluctuations go, Lyell Immunopharma's EPS (Weighted Average and Diluted) skyrocketed by 88.27% in 2021, and later tumbled by 40.86% in 2024.
  • Yearly analysis of 5 years shows Lyell Immunopharma's EPS (Weighted Average and Diluted) stood at -$15.69 in 2020, then skyrocketed by 88.27% to -$1.84 in 2021, then soared by 59.78% to -$0.74 in 2022, then decreased by 25.68% to -$0.93 in 2023, then plummeted by 40.86% to -$1.31 in 2024.